CN113507963A - 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体 - Google Patents

用于晚期实体瘤癌症的治疗性rna及抗pd1抗体 Download PDF

Info

Publication number
CN113507963A
CN113507963A CN202080010292.0A CN202080010292A CN113507963A CN 113507963 A CN113507963 A CN 113507963A CN 202080010292 A CN202080010292 A CN 202080010292A CN 113507963 A CN113507963 A CN 113507963A
Authority
CN
China
Prior art keywords
cancer
rna
tumor
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010292.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·马斯恰里
S·约克
K·许
N·阿夸维拉
M·贝尔纳多
R·贾布洛斯基
U·萨欣
F·吉塞克
Z·吉拉科娃·特恩科娃
T·R·瓦格纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CN113507963A publication Critical patent/CN113507963A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080010292.0A 2019-01-21 2020-01-17 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体 Pending CN113507963A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962794896P 2019-01-21 2019-01-21
US62/794,896 2019-01-21
US201962926379P 2019-10-25 2019-10-25
US62/926,379 2019-10-25
EP19306471.4 2019-11-14
EP19306471 2019-11-14
PCT/US2020/014039 WO2020154189A1 (en) 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Publications (1)

Publication Number Publication Date
CN113507963A true CN113507963A (zh) 2021-10-15

Family

ID=69582159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010292.0A Pending CN113507963A (zh) 2019-01-21 2020-01-17 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体

Country Status (13)

Country Link
US (1) US20220288199A1 (https=)
EP (1) EP3914355A1 (https=)
JP (1) JP2022518236A (https=)
KR (1) KR20210118870A (https=)
CN (1) CN113507963A (https=)
AU (1) AU2020210614A1 (https=)
BR (1) BR112021013965A2 (https=)
CA (1) CA3126110A1 (https=)
IL (1) IL284645A (https=)
MX (1) MX2021008605A (https=)
SG (1) SG11202107396RA (https=)
TW (1) TWI850316B (https=)
WO (1) WO2020154189A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557060A (zh) * 2019-01-21 2021-10-26 赛诺菲 用于晚期实体瘤癌症的治疗性rna
WO2023159930A1 (zh) * 2022-02-28 2023-08-31 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
US12060385B2 (en) 2022-02-28 2024-08-13 Guangzhou Henovcom Bioscience Co., Ltd. Compounds for RNA capping and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428301A (zh) 2017-02-28 2024-07-16 法商賽諾菲公司 治療性rna
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
SG11202106764YA (en) 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN116194142A (zh) 2020-09-03 2023-05-30 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症疼痛的方法
WO2022090203A1 (en) * 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4232068A1 (en) * 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
WO2023279068A1 (en) * 2021-07-02 2023-01-05 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275375A1 (en) * 2012-08-14 2017-09-28 Ibc Pharmaceuticals, Inc. Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
WO2018033254A2 (en) * 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
WO2018160540A1 (en) * 2017-02-28 2018-09-07 Sanofi Therapeutic rna
WO2018167320A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CN113557060A (zh) * 2019-01-21 2021-10-26 赛诺菲 用于晚期实体瘤癌症的治疗性rna

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275375A1 (en) * 2012-08-14 2017-09-28 Ibc Pharmaceuticals, Inc. Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
WO2018033254A2 (en) * 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
WO2018160540A1 (en) * 2017-02-28 2018-09-07 Sanofi Therapeutic rna
WO2018167320A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CN113557060A (zh) * 2019-01-21 2021-10-26 赛诺菲 用于晚期实体瘤癌症的治疗性rna

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOSHE SADE-FELDMAN等: "Resistance to checkpoint blockade therapy through inactivation of antigen presentation", NATURE COMMUNICATIONS, vol. 8, no. 1, 26 October 2017 (2017-10-26), pages 2, XP055514594, DOI: 10.1038/s41467-017-01062-w *
PADMANEE SHARMA等: "Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy", CELL, vol. 168, no. 4, 9 February 2017 (2017-02-09), pages 707, XP029935389, DOI: 10.1016/j.cell.2017.01.017 *
吴荻等: "黑素瘤的免疫治疗研究进展", 细胞与分子免疫学杂志, vol. 32, no. 02, 18 February 2016 (2016-02-18), pages 272 - 279 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557060A (zh) * 2019-01-21 2021-10-26 赛诺菲 用于晚期实体瘤癌症的治疗性rna
WO2023159930A1 (zh) * 2022-02-28 2023-08-31 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
US12060385B2 (en) 2022-02-28 2024-08-13 Guangzhou Henovcom Bioscience Co., Ltd. Compounds for RNA capping and uses thereof

Also Published As

Publication number Publication date
SG11202107396RA (en) 2021-08-30
EP3914355A1 (en) 2021-12-01
CA3126110A1 (en) 2020-07-30
TWI850316B (zh) 2024-08-01
BR112021013965A2 (pt) 2021-09-21
KR20210118870A (ko) 2021-10-01
US20220288199A1 (en) 2022-09-15
IL284645A (en) 2021-08-31
TW202043274A (zh) 2020-12-01
WO2020154189A1 (en) 2020-07-30
MX2021008605A (es) 2021-10-26
JP2022518236A (ja) 2022-03-14
AU2020210614A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
TWI850316B (zh) 用於晚期實性瘤癌症之治療性rna及抗pd1抗體
JP7480248B2 (ja) 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ
TW202142230A (zh) 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法
JP2024038250A (ja) 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
CN106999590A (zh) 免疫检查点抑制剂在中枢神经系统肿瘤中的用途
US20230131598A1 (en) Combination treatment for cancer
CN113396230A (zh) 癌症的诊断和治疗方法
US20220040218A1 (en) Therapeutic RNA for Advanced Stage Solid Tumor Cancers
JP7341130B2 (ja) 癌を治療するための組成物および治療方法
JP2024513247A (ja) 抗ｐｄ－１抗体の皮下投与によるがんの治療方法
WO2026019990A1 (en) Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
HK40011069B (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211015

WD01 Invention patent application deemed withdrawn after publication